---
title: "CVRx | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 15.71 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295142568.md"
datetime: "2026-08-06T20:50:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295142568.md)
  - [en](https://longbridge.com/en/news/295142568.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295142568.md)
---

# CVRx | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 15.71 M

Revenue: As of FY2026 Q2, the actual value is USD 15.71 M, beating the estimate of USD 15.55 M.

EPS: As of FY2026 Q2, the actual value is USD -0.53, missing the estimate of USD -0.5238.

EBIT: As of FY2026 Q2, the actual value is USD -13.03 M.

### Second Quarter 2026 Financial and Operating Results

#### Revenue

-   Total revenue for the three months ended June 30, 2026, was $15.7 million, an increase of 16% compared to $13.589 million for the same period in 2025.
-   U.S. revenue was $14.8 million for the three months ended June 30, 2026, an increase of 21% over $12.3 million for the same period in 2025.
-   Revenue from Europe was $0.9 million for the three months ended June 30, 2026, a decrease of 31% compared to $1.3 million for the same period in 2025.

#### Operational Metrics

-   Gross profit was $13.7 million for the three months ended June 30, 2026, an increase of 20% over $11.450 million for the same period in 2025.
-   Gross margin was 87% for the three months ended June 30, 2026, up from 84% for the same period in 2025.
-   Research and development (R&D) expenses increased by 27% to $3.1 million for the three months ended June 30, 2026, compared to $2.469 million for the same period in 2025.
-   Selling, general and administrative (SG&A) expenses increased by 1% to $23.6 million for the three months ended June 30, 2026, compared to $23.357 million for the same period in 2025.
-   Loss from operations was - $13.023 million for the three months ended June 30, 2026, compared to - $14.376 million for the same period in 2025.
-   Interest expense was - $1.578 million for the three months ended June 30, 2026, compared to - $1.473 million for the same period in 2025.
-   Other income, net, was $0.6 million for the three months ended June 30, 2026, compared to $1.1 million for the same period in 2025.
-   Net loss was - $14.0 million for the three months ended June 30, 2026, compared to a net loss of - $14.7 million for the same period in 2025.

#### Cash Flow and Balance Sheet

-   Cash and cash equivalents were $64.6 million as of June 30, 2026.
-   Net cash used in operating and investing activities was - $8.9 million for the three months ended June 30, 2026, compared to - $8.0 million for the same period in 2025.
-   Total assets were $92.283 million as of June 30, 2026, compared to $104.794 million as of December 31, 2025.
-   Long-term debt was $58.571 million as of June 30, 2026, compared to $49.514 million as of December 31, 2025.

#### Unique Metrics

-   U.S. revenue units totaled 466 for the three months ended June 30, 2026, compared to 391 for the same period in 2025.
-   European revenue units decreased to 40 for the three months ended June 30, 2026, from 61 in the prior year period.
-   Active implanting centers in the U.S. grew to 258 as of June 30, 2026, compared to 240 as of June 30, 2025.
-   The number of sales territories in the U.S. was 56 as of June 30, 2026, compared to 47 as of June 30, 2025.
-   The number of sales territories in Europe remained consistent at 5 as of June 30, 2026.
-   Humana issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026, which is the first of its kind for Barostim.

#### Business Outlook

CVRx, Inc. projects full year 2026 total revenue to be between $58.0 million and $60.0 million, with a gross margin ranging from 86% to 87%. Operating expenses are expected to be between $99.0 million and $101.0 million for the full year 2026. For the third quarter of 2026, the company anticipates total revenue between $13.5 million and $14.5 million.

### Related Stocks

- [CVRX.US](https://longbridge.com/en/quote/CVRX.US.md)

## Related News & Research

- [CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results](https://longbridge.com/en/news/295181057.md)
- [CVRx Q2 revenue beats estimates, outlook cut on sales force, payer challenges](https://longbridge.com/en/news/295142307.md)
- [CVRx Stock Is Falling Overnight: Here's What's Driving the Move](https://longbridge.com/en/news/295191032.md)
- [CVRx CRO Robert John exits; Paul Verrastro named interim head of sales](https://longbridge.com/en/news/295526109.md)
- [CVRx to present at Canaccord Genuity Annual Growth Conference](https://longbridge.com/en/news/294066720.md)